UNSPSC 51332521: Lenperone hydrochloride

This classification denotes an antipsychotic agent C22H23F2NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 96Q0TL6O3G, chemically known as 1-butanone, 4-(4-(4-fluorobenzoyl)-1-piperidinyl)-1-(4-fluorophenyl)-, hydrochloride (1:1), but more generally known as lenperone hydrochloride, which bears US NIH Compound Identifier 32592. European Medicines Agency schedules Lenperone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02889MIG.

UNSPSC 51332521 Lenperone hydrochloride is a Commodity code that in practice covers pharmaceutical products procured by state and local health agencies—though recent state and local solicitations tagged to this code show minimal direct alignment with lenperone specifically. Instead, the indexed opportunities reflect broader pharmaceutical procurement activity: naloxone and drug deactivation systems for emergency response, direct-to-manufacturer prescription programs, and multi-source generic pharmaceuticals and over-the-counter products distributed through wholesaler networks. State and local issuing bodies soliciting under pharmaceutical commodity codes include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and cooperative purchasing alliances spanning multiple jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). These entities acquire pharmaceuticals through various procurement vehicles—traditional IFBs with fixed response dates, RFIs for market intelligence on emerging distribution models, and RFPs for multi-vendor, multi-year supply agreements that often include authorized-wholesaler distribution requirements.

Recent activity is concentrated in the South and Upper Midwest. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023 (note: deadline date predates posting, suggesting a data quality issue in the source). Texas HHS posted an RFI on April 3, 2026, to explore vendor capacity for direct-to-manufacturer prescription fulfillment outside traditional pharmacy benefit manager and group purchasing organization channels. MMCAP, administered by the Minnesota Department of Administration, issued an RFP posted January 20, 2026, with a March 26, 2026, response deadline to establish multi-vendor contracts for generic pharmaceuticals and OTC products distributed through AmerisourceBergen (Cencora), Cardinal Health, and Morris & Dickson; evaluation weights 75 percent on price competitiveness and 10 percent on fixed pricing, with winners providing products to authorized wholesalers effective July 1, 2026. Vendors pursuing these opportunities must demonstrate FDA compliance, cGMP and DSCSA certification, wholesaler relationships with functioning chargeback systems, and willingness to accept administrative fees and performance penalty structures.